GLPG Stock Recent News

The heavy selling pressure might have exhausted for Galapagos (GLPG) as it is technically in oversold territory now. In addition to this technical measure, strong agreement among Wall Street analysts in revising earnings estimates higher indicates that the stock is ripe for a trend reversal.

Galapagos NV (GLPG) is technically in oversold territory now, so the heavy selling pressure might have exhausted. This along with strong agreement among Wall Street analysts in raising earnings estimates could lead to a trend reversal for the stock.

Galapagos NV (NASDAQ:GLPG ) Q3 2023 Earnings Conference Call November 3, 2023 8:00 AM ET Company Participants Sofie Van Gijsel - Head, IR Paul Stoffels - CEO, Chairman, Interim Head, R&D Thad Huston - CFO & COO Jeevan Shetty - Head of Clinical Development, Oncology Conference Call Participants Xian Deng - UBS Dane Leone - Raymond James Johoon Kim - RBC Capital Markets Jason Gerberry - Bank of America Sebastiaan van der Schoot - Kempen Jacob Mekhael - KBC Securities Operator Good day, and thank you for standing by. Welcome to the Galapagos Q3 2023 Financial Results Conference Call.

Galapagos NV (NASDAQ:GLPG ) Q2 2023 Results Conference Call August 4, 2023 8:00 AM ET Company Participants Sofie Van Gijsel - Head, IR Paul Stoffels - CEO, Chairman, Interim Head, R&D Thad Huston - CFO and COO Michele Manto - Chief Commercial Officer Daniele D'Ambrosio - Head of Immunology Conference Call Participants Emily Field - Barclays Jason Gerberry - Bank of America Mike Ulz - Morgan Stanley Brian Balchin - Jefferies Xian Deng - UBS Phil Nadeau - TD Cowen Dane Leone - Raymond James Sebastiaan van der Schoot - Kempen Jacob Mekhael - KBC Securities Operator Good day and thank you for standing by. Welcome to the Galapagos H1 2023 Financial Results Conference Call.

Galapagos' focuses on immunology and oncology, with its flagship Jyseleca being used to treat rheumatoid arthritis and ulcerative colitis in Europe and Japan. The company is also developing CAR-T therapies with encouraging initial safety and efficacy data presented from ongoing Phase 1/2 studies.

Galapagos NV (NASDAQ:GLPG ) Q4 2022 Earnings Conference Call February 24, 2023 8:00 AM ET Company Participants Sofie Van Gijsel - Senior Director of Investor Relations Paul Stoffels - Chief Executive Officer Bart Filius - Chief Operating Officer & President Daniele D'Ambrosio - Head of Immunology Michele Manto - Chief Commercial Officer Conference Call Participants Phil Nadeau - Cowen Peter Verdult - Citi Brian Abrahams - RBC Capital Markets Rosie Turner - Jefferies Dane Leone - Raymond James Suzanne van Voorthuizen - Kempen Operator Good day and thank you for standing by. Welcome to the Galapagos Full Year 2022 Financial Results Call and Webcast.

On February 8th, 2023, Galapagos announced disappointing results of their phase 3 DIVERSITY Crohn's disease study; the company is no longer planning to file an MAA. Galapagos stock fell 8%, and the stock is still hovering around negative $2.0Bn enterprise value territory.

U.S.-listed shares of Galapagos GLPG, +0.41% were down 8.9% in premarket trading on Thursday, the day after the company said an experimental treatment for Crohn's disease missed the primary endpoints in a Phase 3 clinical trial. The drug, filgotinib, is approved to treat rheumatoid arthritis and ulcerative colitis in Europe and Japan.

Mechelen, Belgium; 3 January 202 3 , 22.01 CET; Galapagos NV (Euronext & NASDAQ: GLPG) will participate in the 4 1t h Annual J.P. Morgan Healthcare Conference on January 9 -1 2 , 202 3 .

GLPG is setting to transform its business after a slew of failures. The new CEO is a global expert at this, and I don't see him failing.